Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tsuneaki Tagaya is active.

Publication


Featured researches published by Tsuneaki Tagaya.


Journal of Gastroenterology and Hepatology | 2000

Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection.

Shinichi Kakumu; Satomi Ito; Tetsuya Ishikawa; Yukiko Mita; Tsuneaki Tagaya; Yoshitaka Fukuzawa; Kentaro Yoshioka

Background : Tumour immunity does not seem to be induced effectively in tumour‐bearing hosts, including in patients with hepatocellular carcinoma (HCC). One possible reason is that function of dendritic cells (DC) is decreased in such hosts.


Journal of Gastroenterology | 2003

Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus.

Motohiro Arao; Kenichi Murase; Atsuhiko Kusakabe; Kentaro Yoshioka; Yoshitaka Fukuzawa; Tetsuya Ishikawa; Tsuneaki Tagaya; Kunio Yamanouchi; Hiroshi Ichimiya; Yoichi Sameshima; Shinichi Kakumu

Background: To examine the relationship between hepatitis C virus (HCV) infection and diabetes mellitus (DM) in Japanese populations, a retrospective study was done in 866 patients with chronic viral disease. Methods: The present study included 707 HCV-infected and 159 hepatitis B virus (HBV)-infected patients. The prevalences of HBV- and HCV-related cirrhosis were 32% and 33%, respectively. A case-control study was also conducted to determine the seroprevalence of HCV infection in a cohort of 459 diabetics. Results: The prevalence of DM was higher in HCV-infected patients (20.9%; P < 0.02) than in HBV-infected subjects (11.9%). In the cirrhotic patients, DM was observed in 30.8% of the subjects with HCV compared with 11.8% of those with HBV (P < 0.01). Multivariate analysis revealed that the major independent variables associated with type II DM were male sex (odds ratio, 1.54; p = 0.020) and cirrhosis (odds ratio, 1.97; P = 0.0007). The relative odds of the development of DM were calculated to be 3.2 times higher in HCV-infected cirrhotic patients than in HBV-infected ones. In the case-control study of the diabetic cohort, 10.5% of patients were infected with HCV compared with 1.1% with HBV (P < 0.0001). The results indicate that HCV infection is closely associated with DM, compared with HBV infection. Cirrhosis was an independent risk factor for DM. Conclusions: Taken together, the findings indicate that cirrhosis appears to be a more important predictor of glucose intolerance than HCV infection, and the combination of both factors increases the risk of DM in our populations.


Journal of Gastroenterology and Hepatology | 2003

Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection

Tadashi Maeno; Akihiko Okumura; Tetsuya Ishikawa; Koichi Kato; Fumihiko Sakakibara; Ken Sato; Minoru Ayada; Naoki Hotta; Tsuneaki Tagaya; Yoshitaka Fukuzawa; Shinichi Kakumu

Background and Aim:  Evidence showing a higher prevalence of diabetes mellitus (DM) in patients with chronic hepatitis C virus (HCV) infection has been accumulating. However, the reason why chronic HCV infection promotes DM remains unknown. In the present study, the authors focused on non‐cirrhotic and non‐diabetic patients with chronic HCV infection and evaluated the factors responsible for increases in insulin resistance.


International Journal of Cancer | 1999

Gene mutation of transforming growth factor β1 type II receptor in hepatocellular carcinoma

Keiko Furuta; Sachiko Misao; Kiyoshi Takahashi; Tsuneaki Tagaya; Yoshitaka Fukuzawa; Tetsuya Ishikawa; Kentaro Yoshioka; Shinichi Kakumu

Alteration of transforming growth factor β1 (TGF‐β1) type II receptor (RII) appears to cause unresponsiveness to TGF‐β1 in tumorigenic cells. Defect in the mononucleotide repeat sequence, i.e., poly A region of TGF‐β1RII gene has been reported to be related to replication error‐positive cancer cells. We examined if there is any TGF‐β1RII mutation in a coding microsatellite in hepatocellular carcinoma (HCC). Genomic DNAs were extracted from formalin‐fixed, paraffin‐embedded liver tissues obtained at surgery or autopsy in 3 normal individuals and 96 patients with hepatitis C virus‐induced chronic liver disease; 3 with chronic hepatitis, 20 with liver cirrhosis and 73 with HCC. The DNA was PCR‐amplified at 2 segments of TGF‐β1RII: poly A region which includes the (A)10 microsatellite sequence, and poly GT region. PCR products were directly sequenced. DNA from normal and patients with chronic liver disease contained the 10 wild‐type adenines but 3 cases with liver cirrhosis in whom there were only 9 adenines within poly A tract. This microdeletion of one A resulted in a frameshift and truncated a predicted length of amino acids. In HCC lesions, the same deletion was noted in 4 cases (25%) of well‐differentiated type, 10 (40%) of moderately differentiated type, 18 (53%) of poorly differentiated type. None of the lesions had mutations within the GT region. Our findings indicate that one adenine deletion of poly A microsatellite tract within TGF‐β1RII is frequently detected in patients with HCC, and the mutation may cause the abrogation of the function of TGF‐β1RII gene. Int. J. Cancer 81:851–853, 1999.


Journal of Gastroenterology | 2001

Expression of Fas/Fas ligand (FasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC)

Yoshitaka Fukuzawa; Kiyoshi Takahashi; Keiko Furuta; Tsuneaki Tagaya; Tetsuya Ishikawa; Kaori Wada; Yasukazu Omoto; Takehiko Koji; Shinichi Kakumu

Background. This study was conducted to examine the expression of Fas/Fas ligand (FasL), to elucidate its relationship with tumor-infiltrating lymphocytes (TILs), and to detect possible gene mutation of Fas/FasL in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). Methods. Indirect immunohistochemical staining was performed on formalin-fixed, paraffin-embedded sections of liver biopsy and surgery specimens from five normal livers, and from the livers of 30 patients with HCC. Fas/FasL mRNA-expressing cells and apoptotic cells were detected by in situ hybridization and DNA nick end labeling (TUNEL), respectively. We also performed polymerase chain reaction (PCR)-amplifying and direct sequencing for the Fas/FasL gene. Results. Fas/FasL and its mRNA were localized on the membrane or in the cytoplasm in some HCC cells, as well as hepatocytes. Their expression was enhanced in areas with infiltrating inflammatory cells in the noncancerous regions of liver tissue and on the margins of the cancerous tissue. The positivity rate for TUNEL was elevated along these margins. The labeling index of Fas/FasL was lower in the cancerous liver tissue than in the surrounding noncancerous region (P < 0.01), and tended to decrease in proportion to the malignancy of tumor cells; Fas/FasL expression was not found on poorly differentiated type cancer cells. Fas(−)/FasL(+), FasL-mRNA(+) HCC cells were seen in one specimen of moderately differentiated type. Some CD8+T lymphocytes were TUNEL-positive around the cancerous region. In this study, cancerous and noncancerous tissues in HCC revealed no genetic mutations in any exons of Fas/FasL. Conclusions. These findings suggest that Fas/FasL expression was decreased in proportion to the malignancy of tumor cells, and that infiltrating CD8+T lymphocytes play a role in apoptosis in HCC. The apoptosis in HCC could be regulated by the suppression of Fas/FasL expression, or, sometimes, by the enhancement of FasL expression.


Clinical Imaging | 2005

Advanced dynamic flow imaging with contrast-enhanced ultrasonography for the evaluation of tumor vascularity in liver tumors

Naoki Hotta; Tsuneaki Tagaya; Tadashi Maeno; Minoru Ayada; Ken Sato; Tetsuya Ishikawa; Akihiko Okumura; Yoshitaka Fukuzawa; Shinichi Kakumu


Hepato-gastroenterology | 2003

Usefulness of contrast-enhanced ultrasonography with dynamic flow imaging to evaluate therapeutic effects for hepatocellular carcinoma.

Naoki Hotta; Tsuneaki Tagaya; Tadashi Maeno; Tetsuya Ishikawa; Akihiko Okumura; Yoshitaka Fukuzawa; Shinichi Kakumu


Hepato-gastroenterology | 2005

A case of hepatocellular carcinoma (HCC) treated with radiofrequency ablation (RFA) using 4D real-time ultrasound system.

Naoki Hotta; Yoshitaka Fukuzawa; Minoru Ayada; Ken Sato; Tadashi Maeno; Tsuneaki Tagaya; Akihiko Okumura; Tetsuya Ishikawa; Yuko Ito; Shinichi Kakumu


Hepatology | 2003

1165 Combination therapy of lamivudine and HB vaccine for the treatment of chronic hepatitis B

Tetsuya Ishikawa; Akihiko Okumura; Tadashi Maeno; Ken Sato; Minoru Ayada; Naoki Hotta; Tsuneaki Tagaya; Yoshikata Fukuzawa; Shinichi Kakumu


Hepatology | 2003

672 Establishment of a novel mouse model for AIH type 2

Akihiko Okumura; Tetsuya Ishikawa; Ken Sato; Minoru Ayada; Tadashi Maeno; Naoki Hotta; Tsuneaki Tagaya; Yoshitaka Fukuzawa; Shinichi Kakumu

Collaboration


Dive into the Tsuneaki Tagaya's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Naoki Hotta

Aichi Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tadashi Maeno

Aichi Medical University

View shared research outputs
Top Co-Authors

Avatar

Minoru Ayada

Aichi Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Keiko Furuta

Aichi Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge